Blasius Liss
Overview
Explore the profile of Blasius Liss including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
186
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stemler J, Mellinghoff S, Khodamoradi Y, Sprute R, Classen A, Zapke S, et al.
J Antimicrob Chemother
. 2023 Jun;
78(8):1813-1826.
PMID: 37311136
Patients with haematological malignancies (HM) are at high risk of developing invasive fungal disease (IFD) with high morbidity and attributable mortality. We reviewed data published until September 2021 to update...
2.
3.
Biehl L, Higgins P, Stemler J, Gilles M, Peter S, Dorfel D, et al.
Euro Surveill
. 2022 Jan;
27(2).
PMID: 35027104
BackgroundEvidence supporting the effectiveness of single-room contact precautions (SCP) in preventing in-hospital acquisition of vancomycin-resistant enterococci (haVRE) is limited.AimWe assessed the impact of SCP on haVRE and their transmission.MethodsWe conducted...
4.
Schmalz O, Jacob C, Ammann J, Liss B, Iivanainen S, Kammermann M, et al.
J Med Internet Res
. 2020 Dec;
22(12):e18655.
PMID: 33346738
Background: Cancer immunotherapy (CIT), as a monotherapy or in combination with chemotherapy, has been shown to extend overall survival in patients with locally advanced or metastatic non-small cell lung cancer...
5.
Muller C, Gehlen D, Blaich C, Prozeller D, Liss B, Streichert T, et al.
Ther Drug Monit
. 2017 Jul;
39(5):505-513.
PMID: 28742650
Background: A fast and easy-to-use liquid chromatography-tandem mass spectrometry method for the determination and quantification of 6 triazoles [fluconazole (FLZ), isavuconazole (ISZ), itraconazole (ITZ), hydroxy-itraconazole (OH-ITZ), posaconazole (PSZ), and voriconazole...
6.
Seidel D, Duran Graeff L, Vehreschild M, Wisplinghoff H, Ziegler M, Vehreschild J, et al.
Mycoses
. 2017 Jul;
60(8):508-516.
PMID: 28730644
Rare invasive fungal diseases (IFD) are challenging for the treating physicians because of their unspecific clinical presentation, as well as the lack of standardised diagnostic and effective treatment strategies. Late...
7.
Biehl L, Vehreschild J, Liss B, Franke B, Markiefka B, Persigehl T, et al.
J Antimicrob Chemother
. 2016 Jun;
71(9):2634-41.
PMID: 27317443
Objectives: Antifungal prophylaxis is recommended for haematological patients at high risk of invasive fungal infections (IFIs). Incidence, optimal therapeutic management and outcome of breakthrough IFIs (bIFIs) are largely unknown. Methods:...
8.
9.
Biehl L, Schmidt-Hieber M, Liss B, Cornely O, Vehreschild M
Crit Rev Microbiol
. 2014 Feb;
42(1):1-16.
PMID: 24495097
Background: The prevalence of extended-spectrum β-lactamase producing Enterobacteriaceae (ESBL-E) is increasing worldwide. ESBL-E are known to colonize different body sites and cause bloodstream infections (BSI), pneumonia, intra-abdominal infections and urinary...
10.
Vehreschild J, Birtel A, Vehreschild M, Liss B, Farowski F, Kochanek M, et al.
Crit Rev Microbiol
. 2012 Aug;
39(3):310-24.
PMID: 22917084
Mucormycosis is an emerging invasive fungal infection, primarily affecting immunocompromised patients. The disease is difficult to diagnose and mortality reaches 40% even if treated adequately. Depending on site of infection...